How to use the speech recognition tool?
A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation.
Status of the trial: Active, Recruiting
Orphan Drug Recognition: No
- Opening Date: 2019-03-26
- Closing Date: 2021-08-31
Funder Type: public
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Neuro-Ophthalmology Rare Diseases (WG2)
This ERN is supported by:
Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-Eye